ArticleAlzheimer's research & therapy2020
Prediction of Alzheimer's disease biomarker status defined by the 'ATN framework' among cognitively healthy individuals: results from the EPAD longitudinal cohort study.
Article in Alzheimer's research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Multi-domain prognostic models used in middle-aged adults without known cognitive impairment for predicting subsequent dementia.The Cochrane database of systematic reviews · 2023Pooled it
- Plasma ATN biomarkers across the alzheimer's disease continuum in a Chilean community- and clinic-based cohort.Alzheimer's research & therapy · 2026Article
- Plasma p-tau immunoassays in clinical research for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Cerebrospinal fluid proteomic profiling of cognitively unimpaired individuals with suspected non-Alzheimer's disease pathophysiology.Brain communications · 2025Article
- Association of Vascular Risk Factors and Cerebrovascular Pathology With Alzheimer Disease Pathologic Changes in Individuals Without Dementia.Neurology · 2024Article
- Article
- The clinical importance of suspected non-Alzheimer disease pathophysiology.Nature reviews. Neurology · 2024Review
- Simple modeling of familial Alzheimer's disease using human pluripotent stem cell-derived cerebral organoid technology.Stem cell research & therapy · 2024Article
- Alzheimer's disease diagnostic accuracy by fluid and neuroimaging ATN framework.CNS neuroscience & therapeutics · 2024Article
- Genetic, vascular and amyloid components of cerebral blood flow in a preclinical population.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023Article
- Acute and Chronic Macrophage Differentiation Modulates TREM2 in a Personalized Alzheimer's Patient-Derived Assay.Cellular and molecular neurobiology · 2023Article
- Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders.Alzheimer's research & therapy · 2023Article
- Translational potential of synaptic alterations in Alzheimer's disease patients and amyloid precursor protein knock-in mice.Brain communications · 2023Article
- Identification of preclinical dementia according to ATN classification for stratified trial recruitment: A machine learning approach.PloS one · 2023Article
- Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes.Nature reviews. Neurology · 2022Review
- The European Prevention of Alzheimer's Dementia Programme: An Innovative Medicines Initiative-funded partnership to facilitate secondary prevention of Alzheimer's disease dementia.Frontiers in neurology · 2022Article
- Regional associations of white matter hyperintensities and early cortical amyloid pathology.Brain communications · 2022Article
- Markers of Cerebrovascular Injury, Inflammation, and Plasma Lipids Are Associated with Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Cognitively Normal Persons.Journal of Alzheimer's disease : JAD · 2022Article
- Prediction of Cognitive Progression in Individuals with Mild Cognitive Impairment Using Radiomics as an Improvement of the ATN System: A Five-Year Follow-Up Study.Korean journal of radiology · 2022Article
- Secondary Prevention of Dementia: Combining Risk Factors and Scalable Screening Technology.Frontiers in neurology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundThe Amyloid/Tau/Neurodegeneration (ATN) framework has been proposed as a means of evidencing the biological state of Alzheimer's disease (AD). Predicting ATN status in pre-dementia individuals therefore provides an important opportunity for targeted recruitment into AD interventional studies. We investigated the extent to which ATN-defined biomarker status can be predicted by known AD risk factors as well as vascular-related composite risk scores.
methodsOne thousand ten cognitively healthy older adults were allocated to one of five ATN-defined biomarker categories. Multinomial logistic regression tested risk factors including age, sex, education, APOE4, family history of dementia, cognitive function, vascular risk indices (high systolic blood pressure, body mass index (BMI), high cholesterol, physical inactivity, ever smoked, blood pressure medication, diabetes, prior cardiovascular disease, atrial fibrillation and white matter lesion (WML) volume), and three vascular-related composite scores, to predict five ATN subgroups; ROC curve models estimated their added value in predicting pathology.
resultsAge, APOE4, family history, BMI, MMSE and white matter lesions (WML) volume differed between ATN biomarker groups. Prediction of Alzheimer's disease pathology (versus normal AD biomarkers) improved by 7% after adding family history, BMI, MMSE and WML to a ROC curve that included age, sex and APOE4. Risk composite scores did not add value.
conclusionsATN-defined Alzheimer's disease biomarker status prediction among cognitively healthy individuals is possible through a combination of constitutional and cardiovascular risk factors but established dementia composite risk scores do not appear to add value in this context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.